Cellular signalling pathways mediating the pathogenesis of chronic inflammatory respiratory diseases: an update

M Mehta, DS Dhanjal, KR Paudel, B Singh… - …, 2020 - Springer
Respiratory disorders, especially non-communicable, chronic inflammatory diseases, are
amongst the leading causes of mortality and morbidity worldwide. Respiratory diseases …

Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?

AJ Theron, HC Steel, GR Tintinger… - Drug design …, 2013 - Taylor & Francis
Beta2-adrenoreceptor agonists (β2-agonists) are primarily bronchodilators, targeting airway
smooth muscle and providing critical symptomatic relief in conditions such as bronchial …

Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers

R Vehring, D Lechuga-Ballesteros, V Joshi, B Noga… - Langmuir, 2012 - ACS Publications
Engineered porous phospholipid microparticles with aerodynamic diameters in the
respirable range of 1–2 μm were cosuspended in 1, 1, 1, 2-tetrafluoroethane, a propellant …

Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD

MR Partridge, M Miravitlles, E Ståhl… - European …, 2010 - Eur Respiratory Soc
This report concerns the development and validation of two patient-reported outcomes
questionnaires developed to assess chronic obstructive pulmonary disease (COPD) …

Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma

D Lechuga-Ballesteros, B Noga, R Vehring… - Future medicinal …, 2011 - Future Science
Pressurized metered dose inhaler is the most common inhaled dosage form, ideally suited
for delivering the highly potent compounds that medicinal chemists typically discover for …

Time to define the disorders of the syndrome of COPD

R Beasley, M Weatherall, J Travers, P Shirtcliffe - The Lancet, 2009 - thelancet.com
Whether an adult presenting with symptoms and signs of airflow obstruction has chronic
obstructive pulmonary disease (COPD) or asthma is important, not least because the …

Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4+CD25+Foxp3+regulatory T cells in COPD

L Yang, Q Ma, W Yao, Q Zhang, H Chen, G Wang… - Respiratory …, 2011 - Springer
Background Salmeterol and fluticasone combination (SFC) has anti-inflammatory effects
and improves clinical symptoms in patients with chronic obstructive pulmonary disease …

Proteostasis: a new therapeutic paradigm for pulmonary disease

M Bouchecareilh, WE Balch - Proceedings of the American Thoracic …, 2011 - atsjournals.org
Among lung pathologies, α1AT, chronic obstructive pulmonary disease (COPD),
emphysema, and asthma are diseases triggered by local environmental stress in the airway …

[HTML][HTML] Recomendaciones para la prevención, diagnóstico y tratamiento de la EPOC en la Argentina

JC Figueroa Casas, E Schiavi, JA Mazzei… - Medicina (Buenos …, 2012 - SciELO Argentina
La enfermedad pulmonar obstructiva crónica (EPOC) está aumentando marcadamente su
morbimortalidad, costos e indicadores epidemiológicos. Por ello la Asociación Argentina de …

Optimising pharmacological maintenance treatment for COPD in primary care

R Jones, A Østrem - Primary Care Respiratory Journal, 2011 - nature.com
Chronic obstructive pulmonary disease (COPD) is a multi-faceted disease that is a major
cause of morbidity and mortality worldwide, and is a significant burden in terms of healthcare …